The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases

Britain Baker, Luísa Eça Guimarães, Lucija Tomljenovic, Nancy Agmon-Levin, Yehuda Shoenfeld*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Introduction: With the safety of human papilloma virus vaccine (HPVv) being questioned, this article aims to assess the risks and benefits of the commercially available HPVv. Within the last decade, two vaccines (Gardasil and Cervarix) have been put on the market to prevent infection with the most oncogenic HPV subtypes. Both vaccines contain aluminum adjuvants that are meant to cause a hyper stimulated immune response to prevent HPV infection.Areas covered: The purpose of this paper is to consider the safety of these two vaccines based on the data from the U.S. Vaccine Adverse Event Reporting System (VAERS) and case reports.Expert opinion: The current HPVv are both effective and generally safe. However, it should be noted that autoimmune side effects have been reported in several studies. Further research should be done to understand the relationship between HPVv and autoimmunity.

Original languageEnglish
Pages (from-to)1387-1394
Number of pages8
JournalExpert Opinion on Drug Safety
Issue number9
StatePublished - 2 Sep 2015


  • Adjuvant
  • Aluminum
  • Autoimmune/inflammatory syndrome induced by adjuvants
  • Autoimmunity
  • Guillain barré syndrome
  • Human papilloma virus
  • Postural orthostatic tachycardia syndrome
  • Premature ovarian failure
  • Vaccines


Dive into the research topics of 'The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases'. Together they form a unique fingerprint.

Cite this